-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to Nihon Keizai Shimbun, on the 26th local time, Daiichi Sankyo announced at the board meeting that it had passed a resolution to release 11 mature drugs including the antihypertensive drug "Acecol" and the antibacterial drug "Banan" in Japan.
As of March 31, 2020, the sales price of these 11 drugs was 4.
In fact, as early as July 2018, Daiichi Sankyo had sold the manufacturing and marketing rights of 41 mature drugs in Japan to Alfresa Pharmaceuticals.
In this regard, Daiichi Sankyo said that due to the emergence of generic drugs, the profitability of generic drugs has been lower than that of new drugs.
management
The company plans to develop 7 new molecular entities from 2018 to 2025.
FDAStomach cancer
In addition, at almost the same time, Daiichi Sankyo also recruited Ken Takeshita from Gilead’s cell therapy business unit and appointed him as the head of Daiichi Sankyo’s global R&D department and the interim head of clinical research.
Leave a message here